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Abstract
Background: Given the extent and priority of urinary symptoms there is little evidence available to inform service
provision in relation to the long term effects of interventions. This study aims to determine the long term (6 year)
clinical effectiveness and costs of a new continence nurse led service compared to standard care for urinary symptoms.
Methods: A long term follow-up study of a 2-arm, non-blinded randomised controlled trial that recruited from a
community based population between 1998-2000 in Leicestershire and Rutland UK was undertaken. 3746 men and
women aged 40 years and over were followed up from the original trial. The continence nurse practitioner (CNP)
intervention comprised a continence service provided by specially trained nurses delivering evidence-based
interventions using pre-determined care pathways. The standard care (SC) arm comprised access to existing
primary care including General Practitioner and continence advisory services in the area. Primary outcome:
Improvement in one or more symptom. Secondary outcomes included: a) Leicester Impact scale; b) patient
perception of problem; c) number of symptoms alleviated and cost-effectiveness; all were recorded at long term
follow-up (average 6 years) post-randomisation.
Results: Overall at long-term follow-up (average 6 years) significantly more individuals in the CNP group (72%) had
improved (i.e had fewer symptoms) compared to those in the SC group (67%) (difference of 5% 95% (CI = 0.6 to 9;
p = 0.02)).
Conclusion: The differences in outcome between the two randomised groups shown immediately post treatment
had decreased by half in terms of symptom improvement at long term follow-up. Although the difference was
statistically significant, the clinical significance may not be, although the direction of the difference favoured the
new CNP service.
Background
Urinary symptoms pose a considerable health care burden
with 200 million people suffering from incontinence
worldwide [1]. In the largest comprehensive study of urin-
ary symptoms in a UK general population, the Leicester-
shire MRC incontinence study reported that 29% of men
and 34% of women aged 40 years or over experience clini-
cally significant storage symptoms with considerable
impact on quality of life [2]. Th i sr e p r e s e n t saf i n a n c i a l
burden to the NHS of 1% of its annual budget [3]. Overall
prevalence and service needs will continue to grow as the
population ages. Consequently it is crucial that effective
service interventions with lasting effect that are acceptable
to patients are identified.
Given the extent and high priority of this condition
there is little evidence available to inform service provision
in relation to the long term effects of interventions. The
only available evidence to date is a study by O’Brien et al
1991, 1995 [4,5] that assessed the long-term effectiveness
of nursing interventions for women with urinary inconti-
nence. This study found that 69% (n = 158) of women
who had received treatment by a nurse in the original trial
maintained their improvement at 2 year follow-up.
The Leicestershire MRC incontinence programme ‘A
population laboratory approach to the epidemiology and
evaluation of care’ undertook a randomised controlled
trial (RCT) of a new continence nurse practitioner
(CNP)-led service for urinary symptoms [6], with
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6 months. The new CNP led service proved to be the
most effective with a 10% higher cure rate than standard
care (SC) with statistically and clinically significant
reductions in urgency, frequency and nocturia as well as
incontinence. In addition, quality of life improvements
were greater in users of the CNP led service and higher
levels of patient satisfaction were achieved. This was the
first study to show the effectiveness of nursing services
on urinary storage symptoms (rather than simply incon-
tinence) and associated QOL. This follow-up study
determines the long-term outcomes from this RCT. It is
crucial to establish whether the identified differences in
outcomes between the standard care (SC) service and
the new continence nurse practitioner (CNP) led service
were maintained.
Methods
Design
This study is a follow-up study of a 2-arm, non-blinded
randomised controlled trial that recruited from a com-
munity based population in Leicestershire and Rutland
between 1998-2000 [6]. Follow-up was undertaken in
2006.
Sample
All individuals were recruited to the original trial with
one or more of the following symptoms: incontinence
several times per month or more, or several times a
year plus reported impact [7]; frequency,h o u r l yo r
more, or two hourly plus impact; nocturia, three times
per night, or twice a night plus impact; or urgency,v e r y
strong or overwhelming, or strong with impact.
Randomisation
Randomisation to the original trial was undertaken by
h o u s e h o l df o l l o w i n gi n f o r m e dc o n s e n ta tar a t i oo f4 : 1
(CNP:GP). This allocation was necessary in order to
ensure sufficient numbers in the nested trials (reported
elsewhere) for detrusor overactivity and urodynamic
stress incontinence. The statistical programme SAS was
used to generate the random allocation sequence and
was implemented using sealed envelopes, numbered
sequentially.
Intervention
The participants were randomised to receive either: (i) a
continence service provided by specially trained nurses
delivering evidence-based interventions using pre-deter-
mined care pathways or (ii) standard care which com-
prised usual access to GP and existing continence services.
The duration of the intervention was eight weeks. Full
details of study methods, interventions and 3 and 6 month
outcomes have been reported previously [6].
Follow-up
We followed-up the original participants using a postal
questionnaire (with two reminders) between 5-7 years
later (participants had been recruited over a 3 year per-
iod, mean time to follow-up was 6 years).
Outcome measures
The primary outcome was improvement in one or more
symptoms of which cure (no symptoms) is a subset. This
was assessed using validated symptom severity questions,
comprising the symptoms of incontinence, urgency, fre-
quency and nocturia, obtained by postal questionnaire
[7]. The questions were originally validated for use in an
interviewer assisted questionnaire. In order to assess
their use in a postal questionnaire we undertook a valida-
tion study in a sample of 85 participants stratified by age
and gender. Kappa statistic was used to compare the
interview and postal questionnaire responses for each
question. Overall agreement was good. Most kappa sta-
tistics were over the threshold value of 0.5 indicating
‘moderate’ agreement (the majority were 0.7). The sec-
ondary outcome measures are divided into two groups:
original secondary outcomes, i.e. those which were
recorded at 3 and 6 months and again at long term fol-
low-up, and additional secondary outcomes, i.e. those
that were collected in order to supplement the original
data and take account of important changes e.g. with
regard to symptom sub groups. Original secondary out-
come measures included:, a) Leicester impact scale, a
validated instrument measuring impact on quality of life
[8] (a scale developed for the study - with a range of 0 to
42 (there were 21 items with a maximum score of 2 on
each item); b) patient perception of problem (Question:
How much of a problem would you say you have with
your urinary symptoms?) and satisfaction with current
symptoms (Question: If you had to spend the rest of your
life with urinary symptoms as they are now, how would
you feel? Would you be....); and c) costs. Additional sec-
ondary outcomes included: d) outcomes according to
symptom subgroups; e) predictors of long term improve-
ment; and f) health related quality of life measured using
the EQ5 D at follow-up. These outcomes were identified
to determine whether there we r ea n ys p e c i f i cp r e d i c t o r s
of improvement, for example symptom subgroups that
would enable service providers to target services of the
future to specific groups.
Statistical analysis
Effectiveness of the intervention at long term follow-up
was analysed by ‘intention to treat’.R e s u l t sw e r e
expressed as absolute differences between observed pro-
portion of individuals with each symptom in the two
groups and proportions of individuals who improved
(together with corresponding 95% confidence interval
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tively. A c
2 test was used to test the difference in pro-
portions and a t-test on the absolute difference in
impact score from baseline was used for analysing
impact score. In order to identify whether there were
any identifiable baseline predictors of improvement at
follow-up (in terms of number of symptoms), multivari-
a t el o g i s t i cr e g r e s s i o nw a su sed to both simultaneously
assess the predictive effect of a variety of factors and
also to explore the evidence of any treatment-covariate
interactions. The 2728 patients with follow-up data at
6 years gave the power to detect a minimum clinically
significant difference of 10% (from 50-60%) at the 1%
significance level with over 95% power as the original
trial had been designed specifically to adequately power
a number of small embedded trials.
Costing Study
The original trial estimated the cost-effectiveness of the
nurse led service in terms of cost per symptom alle-
viated and cost per ‘case cured’.T oe x a m i n eh o w
resource usage and hence costs have changed we
included questions for resource use in the long-term fol-
low up survey using similar methodology to the original
trial. These covered: padding, aids and appliances, con-
tacts with healthcare professionals, and use of hospital
services. These questions asked specifically about
resource use and expenditure in the last six months. We
were unable to ask about the whole 5-7 year period due
to unreliable recall. The costs used in the original trial
were based on 2000/1 UK£s. As these would not reflect
current costs we updated the costs in this analysis to
the cost year 2006/7 using relevant recent sources of
unit costs [9-11]. Where costs had been calculated from
data obtained from the earlier trial we updated using
the retail price index [12]. Analysis of missing data indi-
cated that cases with missing data were statistically sig-
nificantly different, and worse, in terms of health and
urinary symptoms (the extent of missing data in the
symptom and QOL data was minimal). For this reason
we imputed missing data using regression-based multi-
ple imputation implemented via the ICE macro in
STATA version 10 [13].
Ethical Approval for this study was given by Leicester-
shire Local Research Ethics Committee Two (LREC
reference:05/Q2502/9).
Results
Of the 3746 individuals who took part in the original
trial and therefore comprised our sample, 332 had died,
107 requested no further contact on completion of the
original trial and 190 had migrated out of county, of the
3117 remaining a response rate of 87% (n = 2728) was
achieved following 3 mailings (Figure 1. flow chart).
There were no significant baseline differences in those
originally recruited (n = 3746) and those who were fol-
lowed up (n = 2728) in terms of age, gender, ethnicity,
long term health or urinary symptoms (Table 1). The
randomised groups were also similar. In addition
we looked at baseline differences between responders
at follow-up, non-responders at follow-up (n = 389),
those who had died since the original trial (n = 332),
those who had migrated out of county (n = 190) and
those who requested after the original trial that they did
not wish to be mailed again (n = 107). Table 1 shows
that each of the groups were broadly similar at baseline
in terms of demographics and urinary symptoms with
the exception of those who died, these individuals were
older and more likely to be male than other responders/
non-responders recorded. The mean length of follow-up
from baseline was 6 years.
Primary Outcome
Improvement/cure in urinary symptoms
Overall, at long-term follow-up significantly more indivi-
duals in the CNP group (72%) had improved (had fewer
symptoms) compared with 67% in the SC group (differ-
ence of 5% (95% CI = 0.6 to 9;p = 0.02)). At 6 years the
proportion reporting no symptoms or ‘cured’ was 31%
in the intervention group and 27% in the SC group (dif-
ference of 4%, (95% CI -0.4 to 8 p = 0.08)). Changes in
individual urinary symptoms (leakage, frequency,
urgency and nocturia) were not significantly different
between the two groups at follow-up (see table 2)
despite a significant difference having been observed at
3 and 6 month follow-ups.
Original Secondary Outcomes
a) Impact on activities and feelings (QoL) Absolute
change from baseline on the overall quality of life scale
was calculated at follow-up to be 4 (Inter Quartile
Range IQR 1-9) in the CNP group and 4 (IQR 1 to 10)
in the SC group. The mean difference (between CNP
and SC) in change from baseline was 0.31 (95% CI:
-0.46 to 1.08), P = 0.4
b) Perception of problem and satisfaction with symp-
toms By long term follow up differences between the
CNP and SC groups in terms of reported ‘no problem’
or ‘mild problem’ and satisfaction with current symp-
toms had diminished. Although in each case the CNP
arm gave more positive responses there was no signifi-
cant differences between the groups (Table 3).
c) Results of the costing study T h er e s u l t so ft h ec o s t -
ing study from the follow up survey are presented in
Table 4. We had complete cost data for 2217 out of
2728 cases.
There were no statistically significant differences in
costs between the CNP and the GP groups. NHS costs
for both men and women were higher in the CNP
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lar for men and women. Costs borne by respondents
themselves were higher for women (due to much higher
spending on pads). Total costs were substantially higher
for the CNP group, due to higher NHS costs in both
males and females.
Additional Secondary Outcomes
d) Outcomes according to symptom sub group Sub
-group analysis was undertaken to determine whether
outcomes were different for specific symptom sub
groups. Those identified were the International Conti-
nence Society (ICS) defined symptom sub-groups of
Urodynamic Stress Incontinence (USI), Overactive blad-
der (OAB) & Mixed symptoms [14]. Table 5 displays
results at long-term follow-up in terms of improvement
(i.e. reduction in the number of symptoms present com-
pared to baseline) and ‘cure’ (i.e. no symptoms present
at follow-up) between the CNP and standard care arms
of the trial stratified by ICS classification (USI, OAB and
Mixed) at baseline (i.e. randomisation). Only for those
patients who received an initial classification of Mixed
did the use of a CNP appear to be statistically signifi-
cantly better than standard care (P = 0.01). The category
‘other’ comprises those without an ICS classification and
included those with individual symptoms of nocturia,
frequency or continuous leakage.
e) Predictors of Long-term Improvement Those patients
randomised into the CNP arm had a 26% (95% CI: 4% to
54%) increased relative odds of improving compared to
the SC arm [Odds Ratio 1.26, 95% CI: 1.04 to 1.54; P =
0.02]. After adjustment for age, gender and baseline ICS
classification there was little change in terms of the esti-
mate of effect of CNP compared to SC [OR 1.25, 95% CI:
1.02 to 1.53, P = 0.03]. Of the other factors considered
only the presence of an initial classification of Mixed
appeared to have any statistically significant relationship
with outcome (i.e. improvement) though there was little
evidence of an interaction between treatment and ICS
classification (P = 0.05). Odds ratios for improvement
were as follows; Mixed cf. OAB 1.07 (95% CI 0.81 to 1.42;
p=0 . 6 ) ,M i x e dcf. USI 1.41 (95% CI 1.07 to 1.85; p =
0.02) and OAB cf. USI 1.31 (95% CI 0.91 to 1.88; p = 0.1)
the ‘mixed’ effect is likely to be due to OAB improvement.
f) EQ-5 D at Follow-up Table 6 shows the results of
the trial in terms of the health related quality of life
instrument EQ-5 D [15] (Euroqol) at follow-up split
* randomised on a 4:1 basis 
† Data at both 3 & 6 months; †† Data at 3 or 6 or neither month 
# lost to follow-up included those who had died, migrated out of county or who requested no further follow-up after the original trial  
Progress of patients through phases of the trial 
 
Original trial participants 
N=3746 
3&6 months 
    6 years 
Full data 
  Responders   Non responders 
     N=1727             N=183 
Full data 
N=2240 
Lost to 
follow-up# 
N=513 
Non-response at 6 
years N=312 
Incomplete data 
  Responders   Non responders 
     N=406           N=129 
Intervention group* 
CNP  n=2958 
Incomplete data 
N=718 
Mailed at 6 years 
N=2445
Responders at 6 years 
N=2133 
Full data 
  Responders   Non responders 
     N=428              N=43 
Full data† 
N=548 
Lost to 
follow-up# 
N=116 
Non-response at 6 
years N=77 
Incomplete data 
  Responders   Non responders 
     N=167           N=34 
Control group* 
Standard care n=788 
Incomplete data†† 
N=240 
Mailed at 6 years 
N=672 
Responders at 6 years 
N=595 
Figure 1 Progress of patients through phases of the trial (separate file).
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Page 4 of 10Table 1 Baseline demographics and clinical characteristics of follow-up participants and non-responders to follow-up
RESPONDERS NON- RESPONDERS
Baseline characteristics of
responders at 6 years
Baseline characteristics of
responders at 6 years
Non-responders to follow-up Do not mail Migrants Deaths
Intervention Standard care
Number of patients 2133 595 389 107 190 332
Age group in years
40-49 (%) 429 (20%) 125 (21%) 110 (29%) 14 (13%) 49 (26%) 7 (2%)
50-59 (%) 644 (30%) 164 (27%) 110 (29%) 40 (37%) 61 (32%) 25 (7%)
60-69 (%) 638 (30%) 183 (31%) 72 (19%) 37 (35%) 46 (24%) 70 (21%)
70-79 (%) 368 (17%) 106 (18%) 69 (18%) 13 (12%) 27 (14%) 139 (42%)
> 80 (%) 54 (3%) 17 (3%) 28 (7%) 3 (3%) 7 (4%) 91 (27%)
Female (%) 1351 (63%) 360 (60%) 259 (67%) 70 (65%) 129 (68%) 130 (39%)
Ethnic group
white (%) 2029 (95%) 561 (94%) 346 (89%) 92 (86%) 181 (95%) 324 (98%)
Long-term illness (%) 773 (36%) 211 (35%) 149 (38%) 43 (40%) 58 (31%) 187 (56%)
Symptoms
Leakage 1713 (80%) 470 (79%) 324 (83%) 89 (83%) 158 (83%) 256 (77%)
Frequency 1121 (52%) 280 (47%) 219 (56%) 49 (46%) 99 (52%) 171 (51%)
Urgency 1359 (64%) 401 (67%) 262 (67%) 67 (63%) 115 (60%) 252 (76%)
Nocturia 714 (33%) 205 (34%) 144 (37%) 35 (33%) 66 (35%) 191 (57%)
Mild or no problem 1158 (54%) 326 (55%) 190 (49%) 63 (59%) 101 (53%) 149 (45%)
Impact-Median (IQR) 5 (2, 10) 4 (2, 9) 6 (2, 11) 5 (2, 11) 5 (3, 11) 4 (1, 10)
Satisfied with current
urinary symptoms for rest
of life
666 (31%) 212 (36%) 92 (24%) 26 (24%) 52 (27%) 110 (33%)
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0according to treatment arm and whether patients
improved, remained the same or worsened at follow-up
compared to baseline. There were no overall differences
in EQ-5 D between the two treatment arms. Although
there were no overall differences in terms of EQ-5 D
between the two treatment arms, those patients who
improved, i.e. had fewer or no symptoms at follow-up
compared to baseline, had statistically higher EQ-5 D
scores than those who did not, and this was seen in
both treatment arms, although there was between
patients who had improved or worsened -0.0036 (-0.06-
0.012, 0005) regardless of trial group.
Discussion
Summary of main findings
In the original trial we had sufficient power to detect a
clinically significant minimum difference in the propor-
tion of individuals who improved their symptoms of
10% to be detected at the 1% significance level with 99%
power. At 6 month follow-up we detected a difference
Table 2 Number of individuals with each symptom and no symptoms at 3 months, 6 months and long term follow-up
(6 years) by randomisation group
Intervention Standard care Difference (95% Cl; P value)
Total
responders
Individuals with
symptoms/event (%)
Total
responders
Individuals with
symptoms/event (%)
Improvement 3-months 2378 1417 (60%) 584 281 (48%) 11% (7 to 16; P = < 0.001)
6 months 2201 1369 (62%) 536 277 (52%) 11% (6 to 15 P < 0.001)
Long term
follow-up
2045 1530(72%) 567 380 (67%) 5% (0.6 to 9; P = 0.02)
No symptoms
(cure)
3-months 2378 591 (25%) 584 88 (15%) 10% (6% to 13%; p < 0.001)
6 months 2201 624 (28%) 536 104 (19%) 9% (5% to 13%; p < 0.001)
Long term
follow-up
2069 643 (31%) 571 156 (27%) 4% (-0.4 to 8; P = 0.08)
Leakage
(several times per
month or more)
Baseline 2958 2392 (82%) 788 618 (79%)
3 months 2483 1567 (63%) 612 428 (70%) -7% (-11% to -3%; p = 0.002)
6 months 2235 1362 (61%) 546 356 (65%) -4% (-9% to 0%; p = 0.066)
Long term
follow-up
2093 1166 (56%) 580 334 (58%) -2% (-6 to 3; P = 0.4)
Frequency
(hourly or more)
Baseline 1563 (53%) 376 (48%)
3 months 2428 723 (30%) 598 219 (37%) -7% (-11% to -2%; p = 0.001)
6 months 2231 539 (24%) 545 182 (33%) -9% (-14% to -5%; p < 0.001)
Long term
follow-up
2098 290 (14%) 576 85 (15%) -1% (-4 to 2; P = 0.6)
Urgency
(very strong or
overwhelming)
Baseline 1927 (65%) 529 (67%)
3 months 2503 819 (33%) 618 248 (40%) -7% (-12% to -3%; p = 0.001)
6 months 2236 682 (31%) 546 228 (42%) -11% (-16% to -7%; p < 0.001)
Long term
follow-up
2108 482 (23%) 583 153 (26%) -3% (-7% to 0.6%;p = 0.09)
Nocturia
(3 times per night
or more)
Baseline 1070 (36%) 285 (36%)
3 months 2502 497 (20%) 617 164 (27%) -7% (-11% to -3%; p < 0.001)
6 months 2236 420 (19%) 547 133 (24%) -6% (-9% to -2%; p = 0.004)
Long term
follow-up
2106 437 (21%) 585 135 (23%) -2% (-6 to 2; P = 0.2)
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Page 6 of 10in improvement of 11% which met the criteria for clini-
cal significance. By long term follow up we detected a
5% difference which whilst a statistically significant
improvement did not reach our threshold for clinical
significance. So, at 6 years, whilst the probability of SC
being superior is less than 1%, so too is the probability
of the difference being greater than 10% (compared with
67% at 6 months (Figure 2).
The improvements in the CNP group shown imme-
d i a t e l yp o s tt r e a t m e n t( a t3a n d6m o n t h s )h a d
decreased (by half) at long term follow up. The follow-
up took place at 6 years therefore the annual ‘drop off’
of effect between the groups was approximately 1%
each year.
Comparison with existing literature
Although this trial has shown no clinically significant
difference between treatment groups at 6 years, the sta-
tistically significant difference of 5% is an improvement
on previous comparable trials which have shown no
difference at all at 6 years. Maintenance of effect is
rarely seen in long term follow-up studies of conserva-
tive interventions for incontinence [16]. Glazener et al
2005 [17] in their 6 year follow-up of a randomised con-
trolled trial of conservative management of postnatal
urinary and faecal incontinence found no differences
between their intervention and standard care groups at
6 years following a 1 year difference of 9%. Similarly
Agur et al (2008) [18] in their eight year follow-up of an
RCT of antenatal pelvic floor muscle training found no
difference between the groups at follow-up.
Strengths and limitations of the study
This study gained a response rate of 87%, this was a
high response rate compared to similar follow-ups at six
years [17].
Secondary outcomes of improvement in impact, per-
ception of their problem and satisfaction with quality of
life seen at 3 and 6 months were not maintained at long
term follow-up.
Table 3 Patient perception of problem and satisfaction with current urinary symptoms at 3 and 6 months and 6 years
presented by randomisation group
Continence Nurse Practitioner Standard Care
Total number of
individuals
Number of individuals
with event
Total number of
individuals
Number of individuals
with event
Difference (95% CI; p-
value)
Mild or no problem
3 months 2468 819 (74%) 614 416 (68%) 6% (2% to 10%; p = 0.003)
6 months 2181 1721 (79%) 545 380 (70%) 9% (5% to 13%; p < 0.001)
Long term follow-
up (6 Years)
2104 1474 (70%) 589 406 (69%) 1% (-3 to 5%;p = 0.6)
Satisfied with current urinary symptoms for rest of life
3 months 2498 1294 (52%) 618 276 (45%) 7% (3% to 12%; p = 0.001)
6 months 2236 1428 (64%) 546 289 (53%) 11% (6% to 16%; p < 0.001)
Long term follow-
up (6 Years)
2109 1152 (55%) 591 306 (52%) 3% (-2 to 7%; P = 0.2)
Table 4 Summary of costs collected retrospectively over the 6-month period prior to the follow-up study
CNP SC CNP v SC
MALE Cost component Mean [SE] (95% CI) Mean [SE] (95% CI) P-value
Total NHS (excl. P) 91.72 [45.00]
(3.42,180.02)
61.61 [32.36]
(-1.90,125.11)
0.2
Total Own Borne 2.25 [5.09]
(-7.73,12.23)
3.89 [4.40]
(-4.75,12.53)
0.6
Total NHS + Own (excl. P) 93.97 [48.17]
(-0.55,188.49)
65.50 [36.43]
(-5.99,136.99)
0.3
FEMALE Cost component Mean [SE] (95% CI) Mean [SE] (95% CI) P-value
Total NHS 84.96 [28.29]
(29.48,140.44)
60.00 [10.40]
(39.61,80.39)
0.2
Total Own Borne 29.22 [6.63]
(16.22,42.21)
27.67 [5.86]
(16.18,39.16)
0.6
Total NHS + Own 114.18 [29.18]
(56.95,171.40)
87.67 [12.36]
(63.44,111.91)
0.2
Updated cost analysis using multiple imputation to deal with missing data (covariates used to impute: 4 urinary symptoms (urgency, leakage, nocturiaa n d
frequency), number of symptoms, age, body mass index & EQ-5D).
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Page 7 of 10For costs at follow-up our most notable finding was
that NHS costs in the CNP arm were higher than those
in the SC arm, though not significantly so. This finding
was surprising given the lack of differences found in the
other variables examined in the course of this study.
However, this may be due to the fact that those in the
CNP arm were familiar with seeking and obtaining spe-
cialist help with their urinary symptoms. A higher pro-
pensity to seek primary care contacts may in turn lead
to more referrals to secondary care and more inpatient
care and surgeries. There were no differences in indivi-
duals own borne costs suggesting that measures taken
by individuals to manage their own symptoms were
similar in the two groups. We found that NHS costs
were similar for men and women. We were able to
exclude many prostate related costs from our calcula-
tions as we could identify prostate related inpatient
stays and drug usage from our estimates (including
these would increase NHS costs from £92 to £123).
Some of the costs related to male urinary symptoms
would still be related to prostate conditions however as
the reasons for services such as contact with GP may
not be related to the underlying condition.
Since the 2002 publication of the ICS standardisation
document [14] the symptom subgroups of USI, OAB
and mixed have become more established and we
wanted to explore whether long term outcomes varied
according to these subgroups. If certain subgroups of
individuals did better at long term follow-up than
others, future services could specifically identify and tar-
get these groups for services in the future. We only
found that those individuals initially classified with
‘mixed’ incontinence did statistically better in the CNP
arm. This may be due to the nature of the service which
was better able to provide more complex care tackling
more than one problem and following up outcomes to
amend treatment interventions in a way that standard
care is less able to do. In addition mixed symptoms
tend to be more severe and may have responded well to
the comprehensive CNP service.
At long term follow-up there is the potential risk of
contamination between treatment arms once a trial is
finished. This was not the case in this study as the CNP
service was specifically set up for study purposes and
funding of the service was not possible following com-
pletion of the research programme. The availability of
generic continence services post trial for each group was
identical. Whilst these services would draw on the edu-
cation and experience of nurses trained within the trial
programme, there was no possibility that those from
standard care would have access to the successful ser-
vice and could be contaminated.
Although the study was not explicitly designed as a
cluster randomised trial, 220 (8%) patients were in the
Table 5 Baseline classification and outcome at long-term follow-up
CNP SC Difference (95% CI) P-value for Interaction
Total Events (%) Total Events (%)
Improvement
USI 233 158 (68) 56 35 (63) 5% (-9 to 19)
OAB 358 254 (71) 123 96 (78) -7% (16 to 2) 0.05
Mixed
Other *
1109
315
832 (75)
202 (64)
297
84
200 (67)
46 (55)
8% (2 to 14)
9% (-3 to 21)
Cure
USI 235 105 (45) 56 19 (34) 11% (-3 to 24)
OAB 363 94 (26) 124 40 (32) -6% (-16 to 3) 0.06
Mixed
Other *
1120
316
261 (23)
165 (52)
300
84
63 (21)
33 (39)
2% (-3 to 8)
13% (1 to 25)
*Includes those with nocturia, frequency or continuous leakage.
Table 6 EQ-5 D at follow-up according to treatment arm and improvement at follow-up
CNP SC Overall
n Mean (SE) n Mean (SE) n Mean (SE)
Improved 1441 0.720 (0.007) 370 0.724 (0.014) 1811 0.721 (0.010)
Same 436 0.705 (0.014) 150 0.716 (0.022) 736 0.685 (0.011)
Worse 118 0.611 (0.029) 32 0.536 (0.056)
Overall 2074 0.710 (0.006) 577 0.701 (0.012)
Difference (95% CI & P-value) 0.008 (-0.018 to 0.034; 0.5) -0.036 (-0.060 to -0.012; 0.005)
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Page 8 of 10same household, i.e. 110 household pairs. The reduction
in power due to this cluster was minimal - the study
was designed to have over 95% power in order to ade-
quately power a number of small embedded trials. In
order to assess any impact on the results, a logistic
regression model for the primary outcome (improve-
ment compared to baseline) and which allowed for the
effect of clustering was used. This gave identical results
to those presented.
We were also interested to know whether there were
any specific predictors of improvement, that again
would enable service providers to target services of the
future to specific groups, however there were no clear
predictors of improvement.
Conclusions
This is the first study to examine the long term effec-
tiveness of a nurse led service on storage symptoms.
The modest effects shown at long term follow up indi-
cate a drop-off of effect with time which is likely to be
related to the fact that the interventions taught at the
initial intervention needed to be continued or periodi-
cally reinforced e.g. pelvic floor exercises and bladder
training. By implementing the initial interventions and
then offering periodic ‘top-ups’ in the form of nurse
contacts with patients to reinforce teaching on bladder
training, fluid and diet advice and pelvic floor exercises,
a lasting effect may be achieved. Such suggestions
would need to be rigorously tested as part of a RCT
with a full economic evaluation, following exploratory
work on the potential components of the proposed
‘top-ups’.
Acknowledgements
This study was funded by the Medical Research Council G0300835. KRA is
partially supported as a NIHR Senior Investigator (NI-SI-0508-10061).
Study Sponsor: University of Leicester
Author details
1Department of Health Sciences, University of Leicester, 22-28 Princess Road
West, Leicester LE1 6TP, UK.
2Mid Yorkshire Hospitals, Aberford Road,
Wakefield,WF1 4DG, UK.
3Wessex Institute University of Southampton,Alpha
House, Enterprise Rd,Southampton Science Park, Chilworth, Southampton
SO16 7NS, UK.
4University of Glamorgan, UK. Glyntaff Campus,Pontypridd,
CF37 1DL, UK.
Authors’ contributions
KSW, KA, CMcG, RPA, DT, NC, and CS contributed to the design of the study,
and KSW supervised the execution of the study and data collection. DC co-
ordinated and undertook data collection and data entry. KRA, NC, DC, KSW,
DAT, analysed the data. All authors were actively involved in checking the
data and critical revisions to the manuscript, which was drafted by all
authors.
Competing interests
The authors declare that they have no competing interests.
Received: 12 May 2010 Accepted: 14 March 2011
Published: 14 March 2011
References
1. Abrams P, Cardozo L, Khoury S, Wein A: Incontinence: 3rd International
Consultation on Incontinence, 2004 Volume 1; Basics and Evaluation. 2005
France: Health Publication Ltd; 2005.
2. McGrother CW, Donaldson MMK, Shaw C, Matthews RJ, Hayward TA,
Dallosso HM, et al: Storage Symptoms of the Bladder: Prevalence, Incidence
and Need for Services in the Uk. BJU International 2004, 93(6):763-769.
3. Turner DA, Shaw C, McGrother CW, Dallosso HM, Cooper NJ: The Cost of
Clinically Significant Urinary Storage Symptoms for Community Dwelling
Adults in the Uk. BJU International 2004, 93(9):1246-1252.
4. O’Brien J, Austin M, Sethi P, O’Boyle P: Urinary-incontinence - prevalence,
need for treatment, and effectiveness of intervention by nurse. British
Medical Journal 1991, 303(6813):1308-1312.
5. O’Brien J, Long H: Urinary incontinence - long-term effectiveness of
nursing intervention in primary care. British Medical Journal 1995,
311(7014):1208.
6. Williams KS, Assassa RP, Cooper NJ, Turner DA, Shaw C, Abrams KR, et al:
Clinical and cost-effectiveness of a new nurse-led continence service: A
randomised controlled trial. British Journal of General Practice 2005,
55(518):696-703.
7. Shaw C, Matthews RJ, Perry SI, Assassa RP, Williams K, McGrother C, et al:
Validity and reliability of an interviewer-administered questionnaire to
measure the severity of lower urinary tract symptoms of storage
abnormality: the Leicester Urinary Symptom Questionnaire. BJU
International 2002, 90(3):205-215.
8. Shaw C, Matthews RJ, Perry SI, Williams K, Spiers N, Assassa RP, et al:
Validity and Reliability of a Questionnaire to Measure the Impact of
Lower Urinary Tract Symptoms on Quality of Life: the Leicester Impact
Scale. Neurourology and Urodynamics 2004, 23(3):229-236.
9. Curtis L: Unit costs of health and social care. Canterbury: PSSRU, University
of Kent; 2007.
10. NHS Reference costs 2006/7. Department of Health 2008 cited 2008
Nov. 26]. [http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/
PublicationsPolicyAndGuidance/DH_082571].
11. British National Formulary 52. BMJ publishing group and RPS Publishing,
London; 2006.
12. Retail Price Index. NationalStatistics 2008 [http://www.statistics.gov.uk/cci/
nugget.asp?ID=21].
13. Royston P: Multiple imputation of missing values: further update of ice,
with an emphasis on interval censoring. Stata Journal 2007, 7(4):445-464.
14. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al: The
standardisation of terminology of lower urinary tract function: report
from the Standardisation Sub-committee of the International
Continence Society. Neurourol Urodyn 2002, 21:167-178.
15. Brooks R: EuroQol: the current state of play. Health Policy 1996,
37(1):53-72.
16. Emmett CLMA, Peters TJ, Fahey T: Three-year follow-up of a factorial
ramdomised controlled trial of two decision aids for newly diagnosed
hypertensive patients. British Journal General Practice 2005, 55:551-553.
Difference in % IMPROVEMENT
í5 0 5 1 01 52 0
Favours CNP Favours SC Clinically Significant
6 years
6 months
Figure 2 Differences in percentage improvement at 6 months
and 6 years in the CNP and standard care arms (separate file).
Williams et al. BMC Health Services Research 2011, 11:58
http://www.biomedcentral.com/1472-6963/11/58
Page 9 of 1017. Glazener CMA, Herbison GP, MacArthur C, Grant A, Wilson PD: Randomised
controlled trial of conservative management of postnatal urinary and
faecal incontinence: six year follow up. BMJ 2005, 330(7487):337.
18. Agur WI, Steggles P, Waterfield M, Freeman RM: The long-term effectiveness
of antenatal pelvic floor muscle training: Eight-year follow up of a
randomised controlled trial. BJOG: An International Journal of Obstetrics and
Gynaecology 2008, 115(8):985-990, Date of Publication: July 2008.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6963/11/58/prepub
doi:10.1186/1472-6963-11-58
Cite this article as: Williams et al.: Long term follow-up of a randomised
controlled trial of services for urinary symptoms. BMC Health Services
Research 2011 11:58.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Williams et al. BMC Health Services Research 2011, 11:58
http://www.biomedcentral.com/1472-6963/11/58
Page 10 of 10